Pieris Pharmaceuticals Inc News - PIRS | Aktien NASDAQ | ADVFN

Euro vs US Dollar

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

Pieris Pharmaceuticals Inc (PIRS)

16,70

0,60

(3,73%)

Geschlossen 05 Dezember 10:00PM

Verzögert um 15 Minuten

16,70

0,00

(0,00%)

Nach Börsenschluss: 12:55AM

Verzögert um 15 Minuten

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Form 3 - Initial statement of beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form EFFECT - Notice of Effectiveness

Form 425 - Prospectuses and communications, business combinations

Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations

Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™...

Form DEF 14A - Other definitive proxy statements

Form ARS - Annual Report to Security Holders

Form 425 - Prospectuses and communications, business combinations

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical...

Form 425 - Prospectuses and communications, business combinations

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Foren

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Pieris Pharmaceuticals

BNP Paribas Issuance

Exchange Traded

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen